Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early Stage Biotech IPOs Join Late-stage Plays In Appealing to Investors

This article was originally published in The Pink Sheet Daily

Executive Summary

With Epizyme as a top performing biotech IPO and bluebird bio primed to go out soon, investor appetite would seem whetted for early stage biotechs on the public market. With improving overall IPO performance, these returns could again become meaningful for more than a few life science VCs.


Related Content

Korea’s Green Gross, Russia’s Pharmstandard Lead $42.5M Argos Financing; Take Local Rights
Rare Form: GSK, NEA Back Orphan Disease Venture Fund
As Some VCs Refill, Others Are Running Out Of Gas
When To Hold ’Em: Post-IPO, VCs Keep Their Cards
Ambit IPO Ambles Out; Portola And Bluebird Prepare
As Some New Listings Thrive, IPO Pipeline Burgeons


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts